Spero Therapeutics, Inc. (SPRO)
| Market Cap | 130.86M |
| Revenue (ttm) | 61.19M |
| Net Income (ttm) | 15.24M |
| Shares Out | 57.90M |
| EPS (ttm) | 0.26 |
| PE Ratio | 8.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,222,022 |
| Open | 2.030 |
| Previous Close | 2.020 |
| Day's Range | 2.010 - 2.325 |
| 52-Week Range | 1.800 - 3.220 |
| Beta | 1.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, man... [Read more]
Financial Performance
Financial StatementsNews
Spero Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, an increase in authorized shares, and a new stock incentive plan. All proposals passed with a quorum present, and voting results will be published in a Form 8-K.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for ...
GSK, Spero Therapeutics announce FDA approval of Utebzi
GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections including ...
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its...
Spero Therapeutics Earnings release: Q1 2026
Spero Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Spero Therapeutics Quarterly report: Q1 2026
Spero Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare ...
Spero Therapeutics Proxy statement: Proxy filing
Spero Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Spero Therapeutics Proxy statement: Proxy filing
Spero Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Spero Therapeutics Proxy statement: Proxy filing
Spero Therapeutics filed a proxy statement on April 13, 2026, providing details for shareholder voting and corporate governance matters.
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare...
Spero Therapeutics Earnings release: Q4 2025
Spero Therapeutics released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Spero Therapeutics Annual report: Q4 2025
Spero Therapeutics has published its Q4 2025 annual report on March 26, 2026.
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare...
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare ...
Spero Therapeutics announces inducement grant under Nasdaq listing rule
Spero Therapeutics (SPRO) announced that on November 3, 2025, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards to…
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare...
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025 Spero's development partner, GSK, plans to s...
Spero Therapeutics Earnings release: Q3 2025
Spero Therapeutics released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Spero Therapeutics Quarterly report: Q3 2025
Spero Therapeutics has published its Q3 2025 quarterly earnings report on November 13, 2025.
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rar...
Spero Therapeutics, GSK announce PIVOT-PO trial efficacy and safety results
Spero Therapeutics (SPRO) and GSK plc (GSK) announced efficacy and safety results of the phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary trac...
PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced efficacy and safety results of the positive pivotal phase 3 PIVO...
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare ...
Spero Therapeutics Earnings Call Transcript: Q2 2025
Phase III trial for tebipenem HBr in cUTI met its primary endpoint and was stopped early for efficacy, with regulatory submission planned by year-end 2025. Revenue rose 39% year-over-year, net loss narrowed, and cash runway now extends into 2028.